Efficacy and Safety of Pimecrolimus Cream in the Long-Term Management of Atopic Dermatitis in Children

PEDIATRICS ◽  
2002 ◽  
Vol 110 (1) ◽  
pp. e2-e2 ◽  
Author(s):  
U. Wahn ◽  
J. D. Bos ◽  
M. Goodfield ◽  
R. Caputo ◽  
K. Papp ◽  
...  
Keyword(s):  
Atopic Dermatitis ◽  
Efficacy And Safety ◽  
Term Management

scholarly journals Efficacy and Safety of a Traditional Herbal Medicine,Hochu-ekki-toin the Long-Term Management ofKikyo(Delicate Constitution) Patients with Atopic Dermatitis: A 6-Month, Multicenter, Double-Blind, Randomized, Placebo-Controlled Study

2010 ◽  
Vol 7 (3) ◽  
pp. 367-373 ◽  
Author(s):  
Hiromi Kobayashi ◽  
Masamitsu Ishii ◽  
Satoshi Takeuchi ◽  
Yoichi Tanaka ◽  
Takahiro Shintani ◽  
...  
Keyword(s):  
Atopic Dermatitis ◽  
Placebo Group ◽  
Controlled Study ◽  
Efficacy Rate ◽  
Topical Steroids ◽  
Efficacy And Safety ◽  
Double Blind ◽  
Severity Scores ◽  
Term Management

Hochu-ekki-tois a traditional herbal (Kampo) medicine that has been shown to be effective for patients withKikyo(delicate, easily fatigable, or hypersensitive) constitution. Previous case reports have suggested that this herbal drug was effective for a certain subgroup of patients with atopic dermatitis (AD). We aimed to evaluate the efficacy and safety ofHochu-ekki-toin the long-term management ofKikyopatients with AD. In this multicenter, double blind, randomized, placebo-controlled study, 91Kikyopatients with AD were enrolled.Kikyocondition was evaluated by a questionnaire scoring system. All patients continued their ordinary treatments (topical steroids, topical tacrolimus, emollients or oral antihistamines) before and after their protocol entry.Hochu-ekki-toor placebo was orally administered twice daily for 24 weeks. The skin severity scores, total equivalent amount (TEA) of topical agents used for AD treatment, prominent efficacy (cases with skin severity score = 0 at the end of the study) rate and aggravated rate (more than 50% increase of TEA of topical agents from the beginning of the study) were monitored and evaluated. Seventy-seven out of 91 enrolled patients completed the 24-week treatment course (Hochu-ekki-to:n= 37, placebo:n= 40). The TEA of topical agents (steroids and/or tacrolimus) was significantly (P< 0.05) lower in theHochu-ekki-togroup than in the placebo group, although the overall skin severity scores were not statistically different. The prominent efficacy rate was 19% (7 of 37) in theHochu-ekki-togroup and 5% (2 of 40) in the placebo group (P= 0.06). The aggravated rate was significantly (P< 0.05) lower in theHochu-ekki-togroup (3%; 1 of 37) than in the placebo group (18%; 7 of 39). Only mild adverse events such as nausea and diarrhea were noted in both groups without statistical difference. This placebo-controlled study demonstrates thatHochu-ekki-tois a useful adjunct to conventional treatments for AD patients withKikyoconstitution. Use ofHochu-ekki-tosignificantly reduces the dose of topical steroids and/or tacrolimus used for AD treatment without aggravating AD.

scholarly journals Substantiation of Using Pimecrolimus 1% Cream in Proactive Therapy of Children with Atopic Dermatitis

2021 ◽  
Vol 20 (5) ◽  
pp. 376-382
Author(s):  
Nikolay N. Murashkin ◽  
Roman A. Ivanov ◽  
Eduard T. Ambarchian ◽  
Roman V. Epishev ◽  
Alexander I. Materikin ◽  
...  
Keyword(s):  
Atopic Dermatitis ◽  
Maintenance Therapy ◽  
Skin Disease ◽  
Pediatric Population ◽  
Efficacy And Safety ◽  
Inflammatory Skin Disease ◽  
High Prevalence ◽  
Proactive Therapy ◽  
Term Maintenance

Atopic dermatitis (AtD) is multifactorial inflammatory skin disease with high prevalence in pediatric population. It is crucial to implement long-term maintenance therapy to prevent AtD exacerbations according to current clinical guidelines and expert reports. The article summarizes the results of the major studies on using pimecrolimus 1% cream. Its efficacy and safety in long-term proactive therapy of children with AtD are presented.

scholarly journals Long-Term Efficacy and Safety of Molidustat for Anemia in Chronic Kidney Disease: DIALOGUE Extension Studies

2019 ◽  
Vol 49 (4) ◽  
pp. 271-280 ◽  
Author(s):  
Tadao Akizawa ◽  
Iain C. Macdougall ◽  
Jeffrey S. Berns ◽  
Thomas Bernhardt ◽  
Gerald Staedtler ◽  
...  
Keyword(s):  
Chronic Kidney Disease ◽  
Kidney Disease ◽  
Hypoxia Inducible Factor ◽  
Efficacy And Safety ◽  
Open Label ◽  
Multicenter Studies ◽  
Parallel Group ◽  
The Mean ◽  
Term Management

Background: Molidustat, a novel hypoxia-inducible factor-prolyl hydroxylase inhibitor, is being investigated for the treatment of anemia associated with chronic kidney disease (CKD). The efficacy and safety of molidustat were recently evaluated in three 16-week phase 2b studies. Here, we report the results of two long-term extension studies of molidustat. Methods: Both studies were parallel-group, open-label, multicenter studies of ≤36 months’ duration, in patients with anemia due to CKD, and included an erythropoiesis-stimulating agent as active control. One study enrolled patients not receiving dialysis (n = 164), and the other enrolled patients receiving hemodialysis (n = 88). The primary efficacy variable for both studies was change in blood hemoglobin (Hb) level from baseline to each post-baseline visit, and safety outcomes included adverse events (AEs). Results: In patients not on dialysis, the mean ± SD Hb concentrations at baseline were 11.28 ± 0.55 g/dL for molidustat and 11.08 ± 0.51 g/dL for darbepoetin. The mean ± SD blood Hb concentrations throughout the study (defined as mean of each patient’s overall study Hb levels) were 11.10 ± 0.508 and 10.98 ± 0.571 g/dL in patients treated with molidustat and darbepoetin, respectively. Similar proportions of patients reported at least one AE in the molidustat (85.6%) and darbepoetin (85.7%) groups. In patients on dialysis, mean ± SD Hb levels at baseline were 10.40 ± 0.70 and 10.52 ± 0.53 g/dL in the molidustat and epoetin groups, respectively. The mean ± SD blood Hb concentrations during the study were 10.37 ± 0.56 g/dL in the molidustat group and 10.52 ± 0.47 g/dL in the epoetin group. Proportions of patients who reported at least one AE were 91.2% in the molidustat group and 93.3% in the epoetin group. Conclusions: Molidustat was well tolerated for up to 36 months and appears to be an effective alternative to darbepoetin and epoetin in the long-term management of anemia associated with CKD.

scholarly journals Pimecrolimus Cream in the Long-Term Management of Atopic Dermatitis in Adults: A Six-Month Study

Dermatology ◽  
2002 ◽  
Vol 205 (3) ◽  
pp. 271-277 ◽  
Author(s):  
Michael Meurer ◽  
Regina Fölster-Holst ◽  
Gottfried Wozel ◽  
Gottfried Weidinger ◽  
Michael Jünger ◽  
...  
Keyword(s):  
Atopic Dermatitis ◽  
Term Management

Maintenance ECT in Affective Disorders

2009 ◽  
Vol 24 (S1) ◽  
pp. 1-1
Author(s):  
D. Barrocas ◽  
R. Coentre ◽  
I. Chendo ◽  
T. Mendes ◽  
M. Abreu ◽  
...  
Keyword(s):  
Affective Disorders ◽  
Hospital Admissions ◽  
Bipolar Depression ◽  
Efficacy And Safety ◽  
Therapeutic Tool ◽  
Frequent Relapses ◽  
Maintenance Ect ◽  
Santa Maria ◽  
Term Management

ECT is the most powerful therapeutic tool in the treatment of acute mood episodes. However, data on the efficacy and safety of ECT in the long term management of affective disorders is lacking, despite overwhelming rates of chronicity and/or frequent relapses among patients with unipolar and bipolar depression. In this presentation we will review the data of the ECT unit of Hospital de Santa Maria, Lisboa, on maintenace ECT (m-ECT) in these patients. We compare intra and inter-individual evolution prior and after the institution of m-ECT. Considering the number of hospital admissions, mood symptoms and other parameters, our data support the use of this technique as a prophylatic approach for patients with mood disorders and a previous good response to ECT in the acute phase of disease.

scholarly journals Predicting the Long-Term Course of Asthma in Wheezing Infants Is Still a Challenge

ISRN Allergy ◽  
2011 ◽  
Vol 2011 ◽  
pp. 1-5 ◽  
Author(s):  
Flore Amat ◽  
Amandine Vial ◽  
Bruno Pereira ◽  
Isabelle Petit ◽  
André Labbe ◽  
...  
Keyword(s):  
Risk Factors ◽  
Atopic Dermatitis ◽  
Allergic Sensitization ◽  
Persistent Asthma ◽  
Inclusion Criteria ◽  
Recurrent Wheezing ◽  
History Of ◽  
Airborne Allergens ◽  
Term Management

Background. In recurrent wheezing infants, it is important to identify those likely to remain asthmatic in order to propose appropriate long-term management. Objective. To establish predictive factors for persistent asthma at adolescence in a population of recurrent wheezing infants. Methods. Retrospective study of 227 infants. Inclusion criteria were age under 36 months, a history of at least three wheezing episodes assessed via a doctor-led ISAAC questionnaire and a standardized allergy testing programme. At 13 years, active asthma was assessed by questionnaire. Results. Risk factors for asthma persisting into adolescence were allergic sensitization to multiple airborne allergens (OR 4.6, CI-95% (1.9–11.2) ), initial atopic dermatitis (OR 3.4, CI-95% (1.9–6.3) ), severe recurrent wheezing (OR 2.3, CI-95% (1.3–4.2) ), and hypereosinophilia ≥470/mm3 (OR 2.2, CI-95% (1.07–4.7) ). Conclusion. While it is still difficult to predict the long-term course of asthma, atopy remains the major risk factor for persistent asthma.

Sign in / Sign up

Export Citation Format

Share Document